Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.56 |
| ▸ | JAK2 | O60674 | 10/20 | 0.56 |
| ▸ | TYK2 | P29597 | 4/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953215 | 0.89 | JAK1 (0.57) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2280497 | 0.88 | JAK2 (0.66) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL9953265 | 0.87 | JAK1 (0.53) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2282018 | 0.86 | JAK1 (0.54) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL9953753 | 0.86 | JAK1 (0.51) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL10281493 | 0.86 | JAK1 (0.58) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2274036 | 0.85 | JAK1 (0.72) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2274555 | 0.85 | JAK1 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2276234 | 0.85 | JAK1 (0.53) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL10281492 | 0.85 | JAK1 (0.51) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |